Spyre Therapeutics, Inc. SYRE Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$69.01M-54.1% | -$62.53M-11.1% | -$11.18M+83.8% | -$36.72M+5.5% | -$44.77M-2.1% | ||
| $12.81M+44.6% | $9.81M+6.5% | $9.57M-27.0% | $9.38M+7.8% | $8.86M-36.0% | ||
| $30M— | -$10M— | $0— | $10M— | $0— | ||
| -$3.21M-206% | $1.45M+132% | $3.75M+93.7% | $23K-81.6% | $3.02M+36.8% | ||
| $3.65M+161% | —— | —— | -$2.3M+85.4% | -$6M-174% | ||
| $233K+150% | $2.88M— | $6.16M— | $4.25M-40.3% | -$462K-221% | ||
| $36K-98.1% | -$3.96M-369% | $3.94M+276% | -$2.52M+60.7% | $1.95M+130% | ||
| -$57.37M-40.0% | -$44.58M-19.8% | -$37.12M-26.2% | -$46.56M+25.2% | -$40.99M-43.6% | ||
| $81.17M+13.6% | $341.71M+46.6% | $74.19M+112% | $34.87M-80.5% | $71.44M-53.2% | ||
| $107.75M+50.9% | $94.3M+50.8% | $99.19M+27.5% | $106.87M+84.6% | $71.38M+49.5% | ||
| $30M— | —— | —— | $7M— | $0— | ||
| $56.58M+92,856% | -$247.41M-45.1% | $25M— | $79M+166% | -$61K+99.9% | ||
| $2.68M+1,128% | $1.75M— | $491K-92.9% | $848K+71.3% | $218K-95.0% | ||
| $12.26M+9,704% | $312.81M+38.7% | -$4.64M-136% | $731K+103% | $125K-99.9% | ||
| $11.46M+128% | —— | -$16.76M— | —— | -$40.93M-206% | ||
| $2.06M-22.1% | $2.09M-13.8% | $1.35M-55.0% | $2.01M-43.5% | $2.64M+9.0% | ||
| $0— | —— | —— | —— | $0— | ||
| -$30.27M-1,361% | —— | $40.4M+316% | —— | $2.4M+658% | ||
| -$3.21M-206% | $1.45M+132% | $3.75M+93.7% | $23K-81.6% | $3.02M+36.8% | ||
| $3.65M+161% | —— | —— | -$2.3M+85.4% | -$6M-174% | ||
| $36K-98.1% | -$3.96M-369% | $3.94M+276% | -$2.52M+60.7% | $1.95M+130% | ||
| $233K+150% | $2.88M— | $6.16M— | $4.25M-40.3% | -$462K-221% | ||
| $372K-29.8% | $61K-91.3% | $309K-32.4% | $1.23M+892% | $530K— | ||
| $107.75M+50.9% | $94.3M+50.8% | $99.19M+27.5% | $106.87M+84.6% | $71.38M+49.5% | ||
| $171K+83.9% | $69K-79.0% | —— | —— | $93K— | ||
| $9.75M— | $14.75M+68.4% | —— | —— | $0— | ||
| —— | $74.1M+37.3% | $74.1M+37.3% | $74.1M+37.3% | $74.1M+37.3% | ||
| $2.68M+1,128% | $1.75M+33.7% | $491K-62.7% | $848K+71.3% | $218K-95.0% | ||
| —— | $0-100% | $0-100% | $0-100% | $0-100% | ||
| $3K— | $107K-44.8% | —— | —— | $0— | ||
| —— | —— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Spyre Therapeutics, Inc. generate?
- Spyre Therapeutics, Inc. (SYRE) generated -$185.6M in operating cash flow over the trailing twelve months.
- Where does Spyre Therapeutics, Inc.'s cash flow data come from?
- Every line is extracted from Spyre Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.